Assessing therapeutic safety and efficacy of Pazopanib, Pembrolizumab plus Axitinib and Nivolumab plus Ipilimumab in Renal Cell Carcinoma: a systematic review and meta-analysis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
| Huvudupphovsman: | |
|---|---|
| Övriga upphovsmän: | |
| Materialtyp: | Lärdomsprov |
| Språk: | English |
| Publicerad: |
Brac University
2024
|
| Ämnen: | |
| Länkar: | http://hdl.handle.net/10361/23931 |